3Fox RI. Treatment of the patient with Sjoegren' s Syndrome [ J ].Rheum Dis Clin North Am, 1992,18: 699- 709.
4Fox RI, Dixon R, Guarrasi V, et al. Treatment of primary Sjoegren's Syndrome with hydroxychloroquine: a retrospective openlabel study[J]. Lupus, 1996,5:31--36.
5Skopouli FN, Jagiello P, Tsifetaki N, et al. Methotrexate in primary Sjoegren' s Syndrome[ J ]. Clin. Exp Rheumatol, 1996, 14:555 --558.
6Fox PC, Atkinson JC, Macyrkski AA, Wolff A, et al. Pilocarpine treatment of salivary gland hypofunction(Xerostomia) and dry mouth[J ]. Arch Intem Med, 1991,151 : 1149-- 1152.
7Wiseman LR, Faulds D. : Oral pilocarpine. A review of its pharmacological properties and clinical potential in xerostomia [ J ]. Drugs,1995,1 : 143-- 155.
8Zimmer AK, Chetoni P, Saettone MF, et al. Evaluation of pilo-carpine - loaded albumin particles as controlled drug delivery systems for the eye, II coadministration with bioadhesive and viscous polymers[J]. Journal of Controlled Release, 1995,33:31--46.
9Loekhart PB, Fox PC, Gentry AC, et al. Pilot study of controlled-release piloearpine in normal subjects[J ]. Oral Surg. Oral Med. Oral Pathol.Oral Radiol Endod, 1996,82:517--524.
10Glenert U. Effects of chronic anethole trithione and amitriptyline treatment on rat parotid gland signalling[J ]. Eur J Pharmscol- Mol Pharmcol Section, 1992,226: 43 -- 52.
8Langeland S,Wouters PF,Claus P,et al.Experimental assessment of a new research tool for the estimation of two-dimensional myocardial strain[J].Ultrasound Med Biol,2006,32(10):1509-1513.
10Vitali C,Bombardieri S,Jonsson R,et al.Classification criteria for Sjogren's syndrome:a revised version of the European criteria proposed by the American-European Consensus Group[J].Ann Rheum Dis,2002,61(6):554-558.
